NEW YORK, September 24, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on the following
equities: Cerus Corporation (NASDAQ: CERS), Cross Country
Healthcare, Inc. (NASDAQ: CCRN), Alder BioPharmaceuticals,
Inc. (NASDAQ: ALDR), Antares Pharma, Inc. (NASDAQ:
ATRS), CEPHEID (NASDAQ: CPHD). On Wednesday, September 23, 2015, Nasdaq ended at
4752.74, down 0.08%, Dow Jones declined 0.31%, to finish the day at
16279.89, and the S&P closed at 1938.76, down 0.20%. Register
for your complimentary reports at the links given below.
--
Cerus Corp
--
Cerus Corp's stock edged lower by 2.42% to close Wednesday's
session at USD 5.24. The company's
shares oscillated between USD 5.14 and USD
5.36. The stock recorded a trading volume of 0.77 million
shares, which was below its 50-day daily average volume of 0.86
million shares and below its 52-week average volume of 1.13 million
shares. Over the last three days, Cerus Corp's shares have declined
by 9.50% and in the past one week it has moved down 5.92%.
Furthermore, over the last three months, the stock has lost 2.60%
while in the past six months, the shares have picked up 30.35%. The
stock is at a price to book ratio of 4.60. The historical PB ratio
is near to 12.08. Additionally, the stock is trading at a price to
sales ratio of 13.93. Sign up and read the free notes on CERS at:
http://www.aciassociation.com/CERS.pdf
--
Cross Country Healthcare Inc
--
The stock of Cross Country Healthcare Inc gained 3.66% to close
Wednesday's session at USD 15.85. The
shares of the company moved in the range of USD 15.40 and USD
16.20. A trading volume of 0.75 million shares was recorded,
which was greater than its 150-day daily average volume of 0.24
million shares and above its 52-week average volume of 0.23 million
shares. Over the last five days, Cross Country Healthcare Inc's
shares have advanced 14.11% and in the past one month, it has
gained a momentum of 9.99%. The company has returned 26.19% in the
last three months, on a compounded total return basis. The stock is
at a price to book ratio of 3.75. The historical PB ratio is near
to 3.01. Further, the stock is trading at a price to cash flow
ratio of 35.25 and price to sales ratio of 0.68. Register for free
on ACI Association and access the latest research on CCRN at:
http://www.aciassociation.com/CCRN.pdf
--
Alder Biopharmaceuticals Inc
--
Alder Biopharmaceuticals Inc's stock decreased by 1.75% to close
Wednesday's session at USD 37.67. The
company's shares fluctuated in the range of USD 36.97 and USD
38.48. A total of 0.67 million shares exchanged hands, which
surpassed its 50-day daily average volume of 0.60 million shares
and was above its 52-week average volume of 0.48 million shares.
Over the last three days Alder Biopharmaceuticals Inc's shares have
declined by 11.92% and in the past one week it has moved down
7.49%. Furthermore, over the last three months, the stock has lost
24.39% and in the past six months, the shares have picked up
35.70%. The company has returned 29.18% in the last half year, on a
compounded total return basis. The complete research on ALDR is
available for free at:
http://www.aciassociation.com/ALDR.pdf
--
Antares Pharma Inc
--
Antares Pharma Inc's stock added 1.09% to close Wednesday's
session at USD 1.85. The company's
shares oscillated between USD 1.80 and USD
1.90. The stock recorded a trading volume of 0.66 million
shares, which was below its 52-week average volume of 0.80 million
shares. Over the last five days, Antares Pharma Inc's shares have
declined by 1.07% while in the past one month, it has gained a
momentum of 2.21%. In addition, over the last three months, the
stock has gained 7.37% and year to date, the shares have shed
28.02%. The stock is at a price to book ratio of 11.47.
Additionally, the stock is trading at a price to sales ratio of
18.69. Free in-depth research on ATRS is available at:
http://www.aciassociation.com/ATRS.pdf
--
CEPHEID
--
CEPHEID's stock declined 0.45% to close Wednesday's session at
USD 50.93. The share price vacillated
between USD 50.27 and USD 52.10. The
stock recorded a trading volume of 0.65 million shares, which was
below its 50-day daily average volume of 0.81 million shares and
above its 52-week average volume of 0.59 million shares. Over the
last three days CEPHEID's shares have declined by 2.02% and in the
past one week it has moved down 3.51%. Moreover, in the last six
months, the stock has lost 4.46% and year to date, the shares have
shed 5.93%. The stock is at a price to book ratio of 9.80. The
historical PB ratio is near to 10.84. Additionally, the stock is
trading at a price to cash flow ratio of 125.01 and price to sales
ratio of 7.17. The complimentary notes on CPHD can be downloaded in
PDF format at: http://www.aciassociation.com/CPHD.pdf
--
About ACI Association:
Active Charter Investors Association ("ACI Association")
produces regular sponsored and non-sponsored reports, articles,
stock market blogs, and popular investment newsletters covering
equities listed on NYSE and NASDAQ and micro-cap stocks. ACI
Association has two distinct and independent departments. One
department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ACI Association has not been compensated; directly or
indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on sound investment judgment and publicly
available information which is believed to be reliable. The
Reviewer and the Sponsor have not performed any independent
investigations or forensic audits to validate the information
herein. Unless otherwise noted, any content outside of this
document has no association with the Author, the Reviewer, or the
Sponsor (collectively referred to as the "Production Team") in any
way. The Production Team is compensated on a fixed monthly basis
and do not hold any positions of interest in any of the securities
mentioned herein. The information in this release has been
sourced from a third party data base.
NO WARRANTY
ACI Association, the Author, the Reviewer and the Sponsor
(collectively referred to as the "Publishers") are not responsible
for any error which may be occasioned at the time of printing of
this document or any error, mistake or shortcoming. No liability is
accepted by the Publishers whatsoever for any direct, indirect or
consequential loss arising from the use of this document. The
Publishers expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, the Publishers do not (1) guarantee the accuracy,
timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The
included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ACI Association nor any party affiliated
with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our
report(s), read our disclosures, or for more information, visit
http://www.aciassociation.com/.
RESTRICTIONS
ACI Association is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.aciassociation.com